Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCG | P05129 | 1/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12611103 | 0.85 | PRKCG (0.40) | PRKCGPRKCAPRKCDKDM4EMAPT | |
| SCHEMBL17864275 | 0.79 | PTK2 (0.41) | PRKCGPRKCAPRKCDKDM4EMAPT | |
| SCHEMBL13822493 | 0.78 | GRIN2D (0.33) | PRKCGPRKCAPRKCD | |
| SCHEMBL3221430 | 0.75 | MEN1 (0.46) | PRKCGPRKCAPRKCDKDM4E | |
| SCHEMBL4110804 | 0.71 | ALOX15 (0.42) | PRKCGPRKCAPRKCDMAPTPTGS2 | |
| SCHEMBL8079998 | 0.71 | KDM4E (0.34) | PRKCGPRKCAPRKCDKDM4EMAPT | |
| SCHEMBL3218240 | 0.71 | HTR2A (0.45) | KDM4EMAPTL3MBTL1 | |
| SCHEMBL14258253 | 0.71 | HTT (0.39) | PRKCGPRKCAPRKCDKDM4EMAPT | |
| SCHEMBL59871 | 0.69 | — | — | |
| SCHEMBL1506627 | 0.69 | PRKCG (0.31) | PRKCGPRKCAPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115353667-A | Method and material for reducing waste | 李蓁蓁 | 2022-11-18 | — | — | CN | disclosed |
| EP-2810943-B1 | SITAXENTAN DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2017-09-27 | — | — | EP | disclosed |
| EP-2810943-B1 | SITAXENTAN DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2017-09-27 | — | — | EP | disclosed |
| EP-2810943-A1 | SITAXSENTAN DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2014-12-10 | — | — | EP | disclosed |
| EP-2810943-A1 | SITAXSENTAN DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-8642014-B2 | Luminescent compounds | SETA BIOMEDICALS, LLC (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642014-B2 | Luminescent compounds | SETA BIOMEDICALS, LLC (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642014-B2 | Luminescent compounds | SETA BIOMEDICALS, LLC (US) | 2014-02-04 | — | — | US | disclosed |
| US-8592470-B2 | Sitaxentan derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-11-26 | — | — | US | disclosed |
| US-20130197045-A1 | SITAXENTAN DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-01 | — | — | US | disclosed |
| US-20130197045-A1 | SITAXENTAN DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-01 | — | — | US | disclosed |
| US-20100266507-A1 | LUMINESCENT COMPOUNDS | SETA BIOMEDICALS, LLC | 2010-10-21 | — | — | US | disclosed |
| US-20100266507-A1 | LUMINESCENT COMPOUNDS | SETA BIOMEDICALS, LLC | 2010-10-21 | — | — | US | disclosed |
| US-20100266507-A1 | LUMINESCENT COMPOUNDS | SETA BIOMEDICALS, LLC | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266507-A1 | LUMINESCENT COMPOUNDS | SQLE, COASY, ZKSCAN2 | PRKCG 412/4885PRKCA 469/4885PRKCD 1014/4885 |
| US-20130197045-A1 | SITAXENTAN DERIVATIVE | CYP4A11, CYP11B1, HSD11B1 | PRKCG 793/4885PRKCA 502/4885PRKCD 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.